五大类别，覆盖生命科学与健康领域全维度的卓越贡献
基础医学研究奖授予在细胞生物学、分子医学、遗传学、免疫学、神经科学等基础医学领域取得突破性研究成果的个人或团队。获奖研究须具备高度原创性，能够在机制层面深化人类对疾病发生、发展及生命过程的理解，并在同行评审期刊发表具有重要影响力的学术论文。学术委员会组织评审专家综合考量研究的科学严谨性、创新深度、潜在临床转化价值及在学术共同体中的引用影响力。本奖项设立以来已成为华人基础医学研究领域最具代表性的荣誉之一，鼓励科研工作者坚守基础研究阵地，追求源头创新，为生命科学的长远进步奠定坚实理论基础。
临床转化创新奖授予成功推动基础研究成果进入临床应用、切实改善患者诊疗结果的研究者与团队。本奖项聚焦"实验室到病床"这一核心价值主张，表彰在新药研发、新型诊断技术、医疗器械创新及治疗方案开发等方面实现重要突破的工作。候选成果须已完成至少II期临床验证或进入产品注册/上市阶段，具备可量化的临床获益数据。评审尤其重视转化过程中的方法论创新，以及申请人在推动多学科交叉协作、打通监管路径方面的系统性贡献。临床转化创新奖是联盟卓越奖体系中产业影响力最为突出的奖项，得到亚太生物医药产业界的广泛认可。
公共健康贡献奖授予在传染病防控、慢性病管理、卫生政策制定、健康促进及卫生体系改革等公共健康领域做出重大贡献的个人或机构代表。本奖项不设学历门槛，兼顾学术研究者、公共卫生从业者及政策制定者，鼓励跨界协作与实践驱动的健康治理创新。获奖工作须具有明确的人群健康改善效果，能够以数据证明其干预措施或政策倡议在实际卫生环境中的有效性与可持续性。联盟尤为重视在资源匮乏地区或特殊流行病学背景下开展的公共健康工作，以及在突发公共卫生事件响应中所展现的专业领导力与社会责任担当。
生物技术突破奖授予在基因编辑、合成生物学、细胞治疗、蛋白质工程、生物信息学及精准医疗技术等生物技术前沿领域取得重大技术突破的研究者与创新团队。本奖项特别关注技术的颠覆性与工程化落地能力——候选成果不仅须展现显著的技术创新性，亦须具备可复制、可规模化的实施路径，或已产生明确的知识产权成果（专利、技术许可等）。学术委员会可邀请产业界代表参与终审咨询，以确保对技术实用价值的独立客观评估。生物技术突破奖是联盟卓越奖中与产业创新生态结合最为紧密的类别，历届获奖成果均引发行业广泛关注与跟进研究。
青年学者新锐奖专门授予在提名截止日前未满35周岁、在生命科学与健康领域展现出卓越研究潜力与独立学术创造力的青年研究者。本奖项于2024年第六届颁奖典礼上正式增设，旨在回应联盟长期以来对青年人才培育的战略承诺。候选人须已独立主持或作为主要负责人完成至少一项有实质性影响的科研工作，并获得所在机构导师及同行的书面提名推荐。学术委员会组织评审专家综合考量候选人的学术成果质量、研究独立性、职业发展轨迹及国际视野。本奖项不以论文数量论英雄，更看重研究思路的原创性与解决真实问题的勇气与能力。每届评选不超过3名获奖者。
Five categories recognize excellence across the full spectrum of life sciences and health.
This award honors individuals or teams with breakthrough achievements in cell biology, molecular medicine, genetics, immunology, neuroscience, and other basic medical fields. Awarded research must demonstrate high originality, deepen mechanistic understanding of disease development or life processes, and be published in influential peer-reviewed journals. Reviewers consider scientific rigor, depth of innovation, translational potential, and citation impact.
This award recognizes researchers and teams that successfully move basic research outcomes into clinical application and measurably improve patient care. It focuses on the alliance's "lab to bedside" value proposition, including new drug development, diagnostics, medical devices, and treatment programs. Candidate achievements should have completed at least Phase II clinical validation or entered registration or commercialization stages.
This award honors major contributions in infectious disease control, chronic disease management, health policy, health promotion, and health system reform. It welcomes academic researchers, public health practitioners, and policymakers, with emphasis on cross-sector collaboration and practice-driven health governance. Awarded work must show clear population-level health improvement and data-supported sustainability.
This award recognizes major technical breakthroughs in gene editing, synthetic biology, cell therapy, protein engineering, bioinformatics, precision medicine, and other biotechnology frontiers. Reviewers focus on both disruptive innovation and engineering feasibility, including reproducibility, scalability, and intellectual property outcomes such as patents or technology licensing.
Established at the sixth award ceremony in 2024, this category honors researchers under 35 years old at the nomination deadline who show outstanding research potential and independent academic creativity in life sciences and health. Candidates should have led or played a principal role in at least one substantively influential research project and receive written recommendations from their institution or peers. No more than three awardees are selected each year.